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Foray is defined as ‘to pillage in search of spoils’ and this is
what Perou et al [1] have done in terms of analyzing gene
expression in human breast cancer by microarray techno-
logy. The technology behind microarrays was developed
over the past several years once it became apparent that
new, more powerful analytical approaches were needed to
utilize the flood of genomic data and resources being
acquired through the various genome projects. Two domi-
nant platforms have evolved; one revolves around in situ
synthesis of oligonucleotide probes on support matrices
and the other consists of physically stamping specific
target DNAs onto solid supports. For economic, flexibility,
and sensitivity reasons, the second platform has become
favored generally by the academic research community.
This latter technology, as well as the gene-clustering soft-
ware that is crucial to data analysis, has been pioneered by
the laboratories of Brown and Botstein at Stanford Univer-
sity [2–4]. Conceptually, the technology is easy to grasp.
RNA from two separate samples is isolated and reverse
transcribed with incorporation of a red and green fluor.
Equivalent fluorescent intensity is hybridized to a chip that
contains thousands of approximately 500–2000 base pair
gene fragments, and relative gene expression is deter-
mined in a pairwise manner.
The Brown and Botstein group selected the subset of
genes from a 5500 complementary DNA chip that were dif-
ferentially expressed in human breast tumors compared with
cultured normal human mammary epithelial cells by three-
fold or greater in three out of 26 arrays. This subset of 1200
genes was then analyzed by gene-clustering analysis.
Several problems have arisen. A minor one – that a gene
that may change dramatically in only one array – is ignored.
In addition, the criteria of a threefold change in gene expres-
sion may exclude biologically important genes with expres-
sion that falls into the ‘noise’ range. A more substantive
problem that needs to be addressed by the microarray com-
munity is the choice of an appropriate reference sample. To
quantify differences, a gene must be expressed in the refer-
ence sample. Diversity and reproducibility are two critical
issues. It is unlikely that the Stanford control (human
mammary epithelial cells) exhibits sufficiently diversified
gene expression to measure quantitatively all of the genes
that were not expressed in the mammary epithelial cells. The
ideal ‘generic’ control would express all genes and would
be a renewable source, thus providing reproducibility. In a
perfect world, all users of microarray technology would
utilize the same ‘generic’ reference sample, and results
could then be compared across experiments and across dif-
ferent laboratories. The microarray community might settle
on RNA from a pool of cell lines of different cell types, or,
even better, from pools of primary cell cultures that exhibit
broadly diverse gene expression patterns.
Nevertheless, a wealth of data has been generated in the
analysis of Perou et al [1]. Specific cell type signatures
were identified. (The cynic will argue that a good patholo-
gist can already provide this information at a fraction of the
cost; however, consider that adequate diagnostic factors
to identify the 30% of node-negative women with 1–2 cm
breast tumors that will go on to develop metastases have
not been identified with current standard methodologies.)
Clusters, or groups, of coexpressed genes were identified
that showed dramatically different expression levels
across the tumor cohort tested. One example was a
cluster of genes that are known to be regulated by the
interferon/STAT1 signal transduction pathway. A poten-
tially more important cluster of genes was the set of genes
that was associated with cell proliferation. This set of
genes was downregulated when cell growth was reduced
in vitro, and was also shown to be highly expressed in all
of the tumors tested that were deemed ‘proliferative’, as
assessed by high Ki-67 staining index. One could poten-
tially select one to two representative genes from eachhttp://breast-cancer-research.com/content/2/1/008
‘cluster’ of genes, and profile paraffin-embedded tumor
sections for these genes by whatever means that are avail-
able (eg in situ hybridization, immunohistochemistry).
What is the value of this technology in enhancing our
understanding of cancer? With the advent of more dense
arrays, we will determine the dimensions of the black box
and perhaps identify some gray areas. The Stanford group
is presently arraying 23000 complementary DNAs on a
single microarray (CM Perou, personal communication).
Although this may only represent 20% of all human genes,
it does represent a nonrandom set of selected genes and
it is likely that most of the genes critical to the process of
transformation are represented. (It will be worthwhile to
examine the full set of expressed genes, but we predict its
major value will be to identify tissue-specific and develop-
mentally specific genes.) In our judgment, expression
studies should be approached with an open mind, and in
most instances investigators should simply let the
observed patterns ‘do the talking’. We do not favor
boutique chips (eg chips composed of all known apop-
totic or cell cycle genes), because it is often the genes
that one does not suspect ahead of time that are the major
players. After all, microarray technology was originally
envisioned to free us from any preconceived ‘prediction’ of
the biology and to let the biology provide us with insights
to formulate better, unbiased hypotheses. Furthermore,
major signal transduction pathways in mammalian cells do
not appear to behave as discrete units transcriptionally.
Also, there is much action taking place post-transcription-
ally that is not addressed by this technology. Imaging
mass spectrometry, and other proteomic approaches
should provide complementary information.
Eventually, one would like to isolate nests of cells in a
tissue from discrete stages in tumor progression and
perform microarray analysis on each stage. Enhanced sen-
sitivity and/or RNA amplification is needed, because
1.5–2 mg messenger RNA or 100 mg of total RNA is
presently required. At the end of the day, one still must
decide on which genes to study further. After this, the
hard part starts. Ultimately, functional genomics equals
good, old-fashioned cell biology. For more information on
microarray technology and resources, visit our website [5]. 
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